Efficacy and Safety of Sintilimab with Anlotinib as First-Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC)

被引：11
|
作者：
Han, B. [1 ]
Chu, T. [2 ]
Zhong, R. [2 ]
Zhong, H. [2 ]
Zhang, B. [1 ]
Zhang, W. [3 ]
Shi, C. [1 ]
Qian, J. [2 ]
Han, Y. [4 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm, Shanghai, Peoples R China
[2] Shanghai Chest Hosp, Shanghai, Peoples R China
[3] Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Wuhan, Hubei, Peoples R China
[4] Shanghai Chest Hosp, Dept Pathol, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
PD-1; inhibitor; multi-target angiogenesis agent; advanced NSCLC;
D O I：
10.1016/j.jtho.2019.08.269
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
JCSE01.11
引用
收藏
页码：S129 / S129
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of Anlotinib in Combination with Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
    Han, B.
    Chu, T.
    Zhang, X.
    Zhong, H.
    Zhang, B.
    Wang, H.
    Gu, A.
    Zhang, W.
    Shi, C.
    Zhong, R.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S398 - S398
  • [2] Efficacy and Safety of Combing Anlotinib and Erlotinib as a First-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Han, B.
    Chu, T.
    Shi, C.
    Zhong, H.
    Zhang, W.
    Zhang, B.
    Zhong, R.
    Zhang, X.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S646 - S647
  • [3] Docetaxel (Taxotere®) as first-line therapy of advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    [J]. ONKOLOGIE, 2003, 26 : 26 - 32
  • [4] Efficacy and safety analysis of anlotinib combined with immunotherapy as second-line therapy for advanced non-small cell lung cancer (NSCLC)
    Shi, Q.
    Xie, Q.
    Lin, H.
    He, Y.
    Zheng, X.
    Zhou, Z.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S1568 - S1568
  • [5] COST-EFFECTIVENESS OF FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Yang, M. C.
    Tan, E. C. H.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A736 - A736
  • [6] First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses
    Gettinger, S. N.
    Hellmann, M. D.
    Shepherd, F. A.
    Antonia, S. J.
    Brahmer, J.
    Chow, L. Q.
    Goldman, J.
    Juergens, R.
    Borghaei, H.
    Ready, N. E.
    Gerber, D. E.
    Nathan, F.
    Shen, Y.
    Harbison, C. T.
    Rizvi, N.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S632 - S632
  • [7] Efficacy and safety of anlotinib in patients with advanced non-small cell lung cancer
    Zhong, Yuejiao
    Wei, Qiang
    Lu, You
    Tang, Xiuliang
    Wang, Zhongqiu
    Chen, Lingxiang
    [J]. JOURNAL OF THORACIC DISEASE, 2020, 12 (10) : 6016 - 6022
  • [8] Efficacy and safety of anlotinib as maintenance therapy in patients with advanced non-small cell lung cancer achieving SD post first-line chemotherapy combined with immunotherapy
    Li, Xiaobing
    Peng, Yi
    Wu, De
    Tang, Jing
    Wu, Yuebing
    [J]. JOURNAL OF CHEMOTHERAPY, 2024,
  • [9] Efficacy and safety of nivolumab combined with standard therapies for first-line therapy of advanced non-small cell lung cancer
    Metzenmacher, Martin
    Christoph, Daniel C.
    [J]. JOURNAL OF THORACIC DISEASE, 2016, 8 (10) : E1254 - E1256
  • [10] The Efficacy and Safety of Apatinib and Anlotinib in Advanced Non-Small Cell Lung Cancer
    Wei, Xiao
    Zhao, Yun
    Yan, Wenyue
    Dai, Qigang
    Wu, Hui
    Miao, Yang
    Huang, Lei
    Liu, Qing
    Zhang, Xuyao
    Wang, Hongxia
    Liu, Yanan
    Zhang, Linlin
    [J]. ONCOTARGETS AND THERAPY, 2024, 17 : 629 - 642
12345